Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 28199492.
- Also identified by DOI 10.1093/cid/cix125.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- Hepatitis D
- Hepatitis Delta Virus
- Tenofovir
- Virus Replication